Lithium and memantine improve spatial memory impairment and neuroinflammation induced by β-amyloid 1-42 oligomers in rats

Neurobiology of Learning and Memory

Volumn 141, Issue , 2017, Pages 84-92

  Budni, J ^a   Feijo D P ^a   Batista Silva, H ^a   Garcez, M L ^a   Mina, F ^a   Belletini Santos, T ^a   Krasilchik, L R ^a   Luz, A P ^a   Schiavo, G L ^a   Quevedo, J ^a,b,c  

^a UNIVERSIDADE DO EXTREMO SUL CATARINENSE   (Brazil)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

Alzheimer's disease; Cytokines; Dementia; Lithium; Memantine; Spatial memory; Amyloid 1 42

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; INTERLEUKIN 1BETA; INTERLEUKIN 4; LITHIUM CARBONATE; MEMANTINE; TUMOR NECROSIS FACTOR; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); LITHIUM; NEUROPROTECTIVE AGENT; PEPTIDE FRAGMENT;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DEMENTIA; FRONTAL CORTEX; HIPPOCAMPUS; LATENT PERIOD; MALE; MONOTHERAPY; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; RADIAL ARM MAZE TEST; RAT; SPATIAL MEMORY; WORKING MEMORY; ANIMAL; BRAIN; CHEMICALLY INDUCED; DRUG EFFECTS; INFLAMMATION; MEMORY DISORDER; METABOLISM; WISTAR RAT;

AMYLOID BETA-PEPTIDES; ANIMALS; BRAIN; INFLAMMATION; INTERLEUKIN-4; LITHIUM; MALE; MEMANTINE; MEMORY DISORDERS; NEUROPROTECTIVE AGENTS; PEPTIDE FRAGMENTS; RATS; RATS, WISTAR; SPATIAL MEMORY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85017354736     PISSN: 10747427     EISSN: 10959564     Source Type: Journal    
DOI: 10.1016/j.nlm.2017.03.017     Document Type: Article

References (85)

1. Aisen, P.S., The potential of anti-inflammatory drugs for the treatment of Alzheimer's disease. The Lancet Neurology 1 (2002), 279–284.
2. Albayrak, A., Halicia, Z., Polatb, B., et al. Protective effects of lithium: A new look at an old drug with potential antioxidative and anti-inflammatory effects in an animal model of sepsis. International Immunopharmacology 16 (2013), 35–40.
3. Alescio-Lautier, B., Michel, B.F., Herrera, C., et al. Visual and visuospatial short-term memory in mild cognitive impairment and Alzheimer disease: Role of attention. Neuropsychology 45 (2007), 1948–1960.
4. Alvarez, G., Muñoz-Montaño, J.R., Satrústegui, J., et al. Regulation of tau phosphorylation and protection against β-amyloid-induced neurodegeneration by lithium. Possible implications for Alzheimer's disease. Bipolar Disorders 4 (2002), 153–165.
5. Barger, S.W., Goodwin, M.E., Porter, M.M., et al. Glutamate release from activated microglia required the oxidative burst and lipid peroxidation. Journal of Neurochemistry 101:5 (2007), 1205–1213.
6. Bauer, M., Alda, M., Priller, J., et al. Implications of the neuroprotective effects of lithium for the treatment of bipolar and neurodegenerative disorders. Pharmacopsychiatry 36 (2003), S250–254.
7. Browne, T.C., McQuillan, K., McManus, R.M., et al. IFN-γ production by amyloid β-specific Th1 cells promotes microglial activation and increases plaque burden in a mouse model of Alzheimer's disease. The Journal of Immunology 190 (2013), 2241–2251.
8. Cai, Z., Zhao, Y., Zhao, B., Roles of glycogen synthase kinase 3 in Alzheimer's disease. Current Alzheimer Research 9:7 (2012), 864–879.
9. Camins, A., Verdaguer, E., Junyent, F., et al. Potential mechanisms involved in the prevention of neurodegenerative diseases by lithium. CNS Neuroscience & Therapeutics 15 (2009), 333–344.
10. Chalecka-Franaszek, E., Chuang, D.M., Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proceedings of the National Academy of Sciences USA 96:15 (1999), 8745–8750.
11. Chen, G., Rajkowska, G., Du, F., et al. Enhancement of hippocampal neurogenesis by lithium. Journal of Neurochemistry 75 (2000), 1729–1734.
12. Chen, S.L., Tao, P.L., Chu, C.H., et al. Low-dose memantine attenuated morphine addictive behavior through its anti-inflammation and neurotrophic effects in rats. Journal of Neuroimmune Pharmacology 7 (2013), 444–453.
13. Chong, T.W., Loi, S.M., Lautenschlager, N.T., Therapeutic advances and risk factor management: Our best chance to tackle dementia?. Medical Journal of Australia 204 (2016), 91–92.
14. Christensen, R., Marcussena, A.B., Wörtweinb, G., et al. Aβ1-42 injection causes memory impairment, lowered cortical and serum BDNF levels, and decreased hippocampal 5-HT2A levels. Experimental Neurology 210 (2008), 164–171.
15. Chuang, D.M., The antiapoptotic actions of mood stabilizers: Molecular mechanisms and therapeutic potentials. Annals of the New York Academy of Sciences 1053 (2005), 195–204.
16. Da Mesquita, S., Ferreira, A.C., Sousa, J.C., et al. Insights on the pathophysiology of Alzheimer's disease: The crosstalk between amyloid pathology, neuroinflammation and the peripheral immune system. Neuroscience and Biobehavioral Reviews 68 (2016), 547–562.
17. De Paula, V.J., Kerr, D.S., Scola, G., et al. Lithium distinctly modulates the secretion of pro- and anti-inflammatory interleukins in co-cultures of neurons and glial cells at therapeutic and sub-therapeutic concentrations. Current Alzheimer Research 13 (2016), 848–852.
18. Diniz, B.S., Teixeira, A.L., Brain-derived neurotrophic factor and Alzheimer's disease: Physiopathology and beyond. Neuromolecular Medicine 13 (2011), 217–222.
19. Fiorentini, A., Rosi, M.C., Grossi, C., et al. Lithium improves hippocampal neurogenesis, neuropathology and cognitive functions in APP mutant mice. PLoS ONE, 5, 2010, e14382.
20. Forlenza, O.V., De-Paula, V.J.R., Diniz, B.S.O., Neuroprotective effects of lithium: Implications for the treatment of Alzheimer's disease and related neurodegenerative disorders. ACS Chemical Neuroscience 5 (2014), 443–450.
21. Foyet, H.S., Hritcu, L., Ciobica, A., et al. Methanolic extract of Hibiscus asper leaves improves spatial memory deficits in the 6-hydroxydopamine-lesion rodent model of Parkinson's disease. Journal of Ethnopharmacology 133 (2011), 773–779.
22. Galimberti, D., Scarpini, E., Progress in Alzheimer's disease. Journal of Neurology 259 (2012), 201–211.
23. Gauthier, S., Molinuevo, J.L., Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe Alzheimer's disease. Alzheimers Dementia 9 (2013), 326–331.
24. Geldmacher, D.S., Alzheimer's disease: Current pharmacotherapy in the context of patient and family needs. Journal of the American Geriatrics Society 51 (2003), S281–S325.
25. Haass, C., Take five-BACE and the gamma-secretase quartet conduct Alzheimer's amyloid beta peptide generation. EMBO Journal 23 (2004), 483–488.
26. Haass, C., Kaether, C., Thinakaran, G., et al. Trafficking and proteolytic processing of APP. Cold Spring Harbor Perspectives in Medicine, 2, 2012, a006270.
27. Haass, C., Selkoe, D.J., Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer's amyloid bold beta-peptide. Nature Reviews Molecular Cell Biology 8 (2007), 101–112.
28. Hashimoto, R., Fujimaki, K., Jeong, M.R., Christ, L., Chuang, D.M., Lithium-induced inhibition of Src tyrosine kinase in rat cerebral cortical neurons: A role in neuroprotection against N-methyl-D-aspartate receptor-mediated excitotoxicity. FEBS Letters 538:1–3 (2003), 145–148.
29. Heneka, M.T., Kummer, M.P., Weggen, S., et al. Molecular mechanisms and therapeutic application of NSAIDs and derived compounds in Alzheimer's disease. Current Alzheimer Research 8 (2011), 115–131.
30. Heppner, F.L., Ransohoff, R.M., Becher, B., Immune attack: The role of inflammation in Alzheimer disease. Nature Reviews Neuroscience 16 (2015), 358–372.
31. Herrup, K., 2010. (Avila, Wandosell et al., Agnew-Blais, Wassertheil-Smoller et al.)(Avila, Wandosell et al., Agnew-Blais, Wassertheil-Smoller et al.)Reimagining Alzheimer's disease—an age-based hypothesis. Journal of Neuroscience 30, 16755–16762.
32. Hidalgo, M.J.J., Alvarez, X.A., Cacabelos, R., et al. Neuroprotection by memantine against neurodegeneration induced by beta-amyloid (1-40). Brain Research 958 (2002), 210–221.
33. Hong, M., Chen, D.C., Klein, P.S., et al. Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3. Journal of Biological Chemistry, 272, 1997 25326e25332.
34. Hritcu, L., Cioanca, O., Hancianu, M., Effects of lavender oil inhalation on improving scopolamine-induced spatial memory impairment in laboratory rats. Phytomedicine 19 (2012), 529–534.
35. Hu, N.W., Ondrejcak, T., Rowan, M.J., Glutamate receptors in preclinical research on Alzheimer's disease: Update on recent advances. Pharmacology, Biochemistry and Behavior 100 (2012), 855–862.
36. Jack, C.R. Jr, Knopman, D.S., Jagust, W.J., et al. Tracking pathophysiological processes in Alzheimer's disease: An updated hypothetical model of dynamic biomarkers. The Lancet Neurology 12 (2013), 207–216.
37. Johnson, K.A., Fox, N.C., Sperling, R.A., et al. Brain imaging in Alzheimer disease. Cold Spring Harbor Perspectives in Medicine, 2, 2012, a006213.
38. Johnson, J.W., Kotermanski, S.E., Mechanism of action of memantine. Current Opinion in Pharmacology 6 (2006), 61–67.
39. Kahlfuβ, S., Narasimhulu, S., Mankiewicz, J., et al. Immunosuppression by N-Methyl-D-Aspartate receptor antagonists is mediated through inhibition of Kv1.3 and KCa3.1 channels in T cells. Molecular and Cellular Biology 34 (2014), 820–831.
40. Kawasaki, Y., Zhang, L., Cheng, J.K., et al. Cytokine mechanisms of central sensitization: Distinct and overlapping role of interleukin-1β, interleukin-6, and tumor necrosis factor-α in regulating synaptic and neuronal activity in the superficial spinal cord. Journal of Neuroscience 28 (2008), 5189–5194.
41. Kiyota, T., Okuyama, S., Swan, R.J., et al. CNS expression of anti-inflammatory cytokine interleukin-4 attenuates Alzheimer's disease-like pathogenesis in APP + PS1 bigenic mice. The FASEB Journal 24 (2010), 3093–3102.
42. Knijff, E.M., Breunis, M.N., Kupka, R.W., et al. An imbalance in the production of IL-1beta and IL-6 by monocytes of bipolar patients: Restoration by lithium treatment. Bipolar Disorders 9:7 (2007 Nov), 743–753.
43. Laferla, F.M., Green, K.N., Animal models of Alzheimer's disease. Cold Spring Harbor Perspectives in Medicine, 2, 2012, a006320.
44. Lee, S.Y., Chen, S.L., Chang, Y.H., et al. The effects of add-on low-dose memantine on cytokine levels in bipolar II depression: A 12-week double-blind, randomized controlled trial. Journal of Clinical Psychopharmacology 34 (2014), 337–343.
45. Leifer, B.P., Alzheimer's disease: Seeing the signs early. Journal of the American Academy of Nurse Practitioners 21 (2009), 588–595.
46. Li, H., Li, Q., Du, X., et al. Lithium-mediated long-term neuroprotection in neonatal rat hypoxia-ischemia is associated with antiinflammatory effects and enhanced proliferation and survival of neural stem/progenitor cells. Journal of Cerebral Blood Flow and Metabolism 31 (2011), 2106–2115.
47. Liu, M.Y., Wang, S., Yao, W.F., et al. Memantine improves spatial learning and memory impairments by regulating NGF signaling in APP/PS1 transgenic mice. Neuroscience 273 (2014), 141–151.
48. Lowry, O.H., Rosebrough, N.J., Farr, A.L., et al. Protein measurement with the folin phenol reagent. Journal of Biological Chemistry 193 (1951), 265–275.
49. Ma, L., Liu, W., Feng, D., et al. Protective effect of NMDA receptor antagonist memantine on acute lung injury in mice. Journal of Central South Medical University Sciences 39 (2014), 12–16.
50. Machado-Vieira, R., Manji, H.K., Zarate, C.A., The role of lithium in the treatment of bipolar disorder: Convergent evidence for neurotrophic effects as a unifying hypothesis. Bipolar Disorders 11 (2009), 92–109.
51. Martin, M., Rehani, K., Jope, R.S., et al. Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nature Immunology 6 (2005), 777–784.
52. Morgan, D., Diamond, D.M., Gottschall1, P.E., et al. Aβ vaccination prevents memory loss in na animal model of Alzheimer's disease. Nature 408 (2000), 982–985.
53. Mury, F.B., Da Silva, W.C., Barbosa, N.R., et al. Lithium activates brain phospholipase A2 and improves memory in rats: Implications for Alzheimer's disease. European Archives of Psychiatry and Clinical Neuroscience 266 (2015), 607–618.
54. Nahman, S., Belmaker, R.H., Azab, A.N., Effects of lithium on lipopolysaccharide-induced inflammation in rat primary glia cells. Innate Immunity 18 (2012), 447–458.
55. Nonaka, S., Hough, C.J., Chuang, M., Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxicity by inhibiting N-methyl-D-aspartate receptor-mediated calcium influx. Proceedings of the National Academy of Sciences of the United States of America 95 (1998), 2642–2647.
56. Nunes, M.A., Schöwe, N.M., Monteiro-Silva, K.C., et al. Chronic microdose lithium treatment prevented memory loss and neurohistopathological changes in a transgenic mouse model of Alzheimer's disease. PLoS ONE, 10, 2015, e0142267.
57. Nunes, M.A., Viel, T.A., Buck, H.S., Microdose lithium treatment stabilized cognitive impairment in patients with Alzheimer's disease. Current Alzheimer Research 10 (2013), 104–107.
58. Pasquier, F., Grymonprez, L., Lebert, F., et al. Memory impairment differs in frontotemporal dementia and Alzheimer's disease. Neurocase 7 (2001), 161–171.
59. Phiel, C.J., Wilson, C.A., Lee, V.M., et al. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature 423 (2003), e435–e439.
60. Pozueta, J., Lefort, R., Shelanski, M.L., Synaptic changes in Alzheimer's disease and its models. Neuroscience 251 (2013), 51–65.
61. Qaseem, A., Santaguida, P., Ismaila, A., et al. Current pharmacologic treatment of dementia: A clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Annals of Internal Medicine 148 (2008), 370–378.
62. Rai, S., Kamat, P.K., Nath, C., et al. A study on neuroinflammation and NMDA receptor function in STZ (icv) induced memory impaired rats. Journal of Neuroimmunology 254 (2013), 1–9.
63. Raina, P., Santaguida, P., Ismaila, A., et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: Evidence review for a clinical practice guideline. Annals of Internal Medicine 148 (2008), 379–397.
64. Rapaport, M.H., Manji, H.K., The effects of lithium on ex vivo cytokine production. Biological Psychiatry 50 (2001), 217–224.
65. Reisberg, B., Doody, R., Stöffler, A., et al. Memantine in moderate-to-severe Alzheimer's disease. New England Journal of Medicine 348 (2003), 1333–1341.
66. Resende, R., Ferreiro, E., Pereira, C., et al. Neurotoxic effect of oligomeric and fibrillar species of amyloid-beta peptide 1-42: Involvement of endoplasmic reticulum calcium release in oligomer-induced cell death. Neuroscience 155 (2008), 725–737.
67. Riverol, M., Slachevsky, A., López, O.L., Efficacy and tolerability of a combination treatment of memantine and donepezil for Alzheimer's disease: A literature review evidence. European Journal of Neuroscience 3 (2011), 15–19.
68. Robinson, D.M., Keating, G.M., A review of its use in Alzheimer's disease. Drugs 66 (2006), 1515–1534.
69. Rockenstein, E., Torrance, M., Adame, A., et al. Neuroprotective effects of regulators of the glycogen synthase kinase-3beta signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation. Journal of Neuroscience, 27, 2007, 1981e1991.
70. Ruiz-Muñoz, A.M., Nieto-Escamez, F.A., Aznar, S., et al. Cognitive and histological disturbances after chlorpyrifos exposure and chronic Aβ (1-42) infusions in Wistar rats. Neurotoxicology 32 (2011), 836–844.
71. Rybakowski, J.K., Lithium in neuropsychiatry: A 2010 update. The World Journal of Biological Psychiatry 12 (2011), 340–348.
72. Salloway, S., Correia, S., Alzheimer disease: Time to improve its diagnosis and treatment. Cleveland Clinic Journal of Medicine 76 (2009), 49–58.
73. Savchenko, V.L., Regulation of NADPH oxidase gene expression with PKA and cytokine IL-4 in neurons and microglia. Neurotoxicity Research 23:3 (2013), 201–213.
74. Serrano-Pozo, A., Frosch, M.P., Masliah, E., et al. Neuropathological alterations in Alzheimer disease. Cold Spring Harbor Perspectives in Medicine, 1, 2011, a006189.
75. Shankar, G.M., Amyloid β protein dimers isolated directly from Alzheimer brains impair synaptic plasticity and memory. Nature Medicine 14 (2008), 837–842.
76. Small, S.A., Duff, K., Linking Abeta and tau in late-onset Alzheimer's disease: A dual pathway hypothesis. Neuron, 60, 2008, 534e542.
77. Smith, D.A., Treatment of Alzheimer's disease in the long-term-care setting. American Journal of Health System Pharmacy 66 (2009), 899–907.
78. Sonkusare, S.K., Kaul, C.L., Ramarao, P., Dementia of Alzheimer's disease and other neurodegenerative disorders – Memantine, a new hope. Pharmacological Research 51:1 (2005), 1–17 Jan.
79. Ueda, K., Fukui, Y., Kageyama, H., Amyloid β protein-induced neuronal cell death: Neurotoxic properties of aggregated amyloid β protein. Brain Research 639 (1994), 240–244.
80. Varvel, N.H., Bhaskar, K., Kounnas, M.Z., et al. NSAIDs prevent, but do not reverse, neuronal cell cycle reentry in a mouse model of Alzheimer disease. The Journal of Clinical Investigation 119 (2009), 3692–3702.
81. Wang, Y., Huang, W.C., Wang, C.Y., et al. Inhibiting glycogen synthase kinase-3 reduces endotoxaemic acute renal failure by down-regulating inflammation and renal cell apoptosis. British Journal of Pharmacology 157 (2009), 1004–1013.
82. Wu, H.M., Tzeng, N.S., Qian, L., et al. Novel Neuroprotective mechanisms of memantine: Increase in neurotrophic factor release from astroglia and anti-inflammation by preventing microglial over-activation. Neuropsychopharmacology 34 (2009), 2344–2357.
83. Yirmiya, R., Goshen, I., Immune modulation of learning, memory, neural plasticity and neurogenesis. Brain, Behavior, and Immunity 25 (2011), 181–213.
84. Zhang, R., Miller, R.G., Madison, C., et al. Systemic immune system alterations in early stages of Alzheimer's disease. Journal of Neuroimmunology 256 (2013), 38–42.
85. Zhao, L., Gongb, N., Liuc, M., et al. Beneficial synergistic effects of microdose lithium with pyrroloquinoline quinone in an Alzheimer's disease mouse model. Neurobiology of Aging 35 (2014), 2736–2745.